Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. - Test2 - elhamkhani - TriplyDB

Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience.

Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience.

http://www.wikidata.org/entity/Q38062852

about

Advancing Treatment of Pituitary Adenomas through Targeted Molecular Therapies: The Acromegaly and Cushing Disease Paradigms Recent advances in the management of acromegaly Dopamine and Somatostatin Analogues Resistance of Pituitary Tumors: Focus on Cytoskeleton Involvement Pasireotide: a novel treatment for patients with acromegaly Factors associated with biochemical remission after microscopic transsphenoidal surgery for acromegaly.A structural and functional acromegaly classification Growth hormone tumor histological subtypes predict response to surgical and medical therapy.Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors Growth hormone-producing pituitary adenomas in childhood and young adulthood: clinical features and outcomes.New therapeutic agents for acromegaly.Clinical Impact of the Current WHO Classification of Pituitary Adenomas.The role of combination medical therapy in the treatment of acromegaly.Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary.Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance.Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review.Elucidating the Role of the Desmosome Protein p53 Apoptosis Effector Related to PMP-22 in Growth Hormone Tumors.Novel Somatostatin Receptor Ligands Therapies for Acromegaly.Association between radiological parameters and clinical and molecular characteristics in human somatotropinomas.International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature Aggressive Pituitary Tumors or Localized Pituitary Carcinomas: Defining Pituitary Tumors Updates in Diagnosis and Treatment of Acromegaly

P2860

Q26741707-233F158A-D573-435D-A2C0-44964A5DAF9C Q26766199-E6358C87-4609-42C9-AC7E-B2460296D6B6 Q26770701-C6664595-C971-4D77-BAA9-A985EE133785 Q26774437-7CA71FC7-33A2-4095-9588-AB55AB8FB92D Q30408371-A77F162D-A1FE-40C1-9721-9B845E49E08A Q34810811-BAA69260-BC0E-47D6-BE01-DB5175855D7B Q35091578-4A53F0B1-B4A0-4D9E-AF99-BD6C22F8D9CA Q36270932-4F61EC6B-17A7-4726-8528-3CF0442CF232 Q38604420-5FB6F807-89F1-4617-9A48-01C838D4DD4D Q38648739-D28FEE16-7F5A-41B7-A6BD-3F8631B4677B Q38727622-22D2BB5F-75AF-4F5A-9296-CFB2C5AA4862 Q38927318-5D2D206A-3847-4AFA-8B06-03F3872E4103 Q38944306-A7E67711-0808-476E-9AA7-7757C7AF3BDE Q38990078-75F2F107-9A53-4156-A68F-6285D7869040 Q42378746-70DA7C9D-EDFF-44D7-852B-EB1E3E279B00 Q47939983-31755831-8716-4181-996A-9DD84BD37377 Q52643700-9CDB4B58-9CB8-4A11-9CC7-8AF482EDC26B Q55074584-385DABAD-ABD9-425F-A112-04B55850E366 Q57144951-F1A4EAD5-523B-46FD-B4AC-19A39D825ECA Q57793628-1011A51A-4986-4ED8-8EB3-2493D7BE4E66 Q57822729-B9FBA73A-A34C-4955-B353-322D68D48833

P2860

Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience.

http://www.wikidata.org/entity/Q38062852

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Growth hormone granulation pat ...... arge single center experience.

@en

type

label

Growth hormone granulation pat ...... arge single center experience.

@en

prefLabel

Growth hormone granulation pat ...... arge single center experience.

@en

P1433

Q38062852-EB83DF61-5A95-46BF-AF50-80CCFE5364DA

P1476

Q38062852-1067B074-1EC2-44DE-9E26-4E79B35EFB0E

P2093

Q38062852-58943F2B-4A20-401F-B80F-922816EF5B23

Q38062852-72425317-60BE-44DC-8574-C25DB6A54656

Q38062852-786B819A-BBF6-4F76-A956-8B7B9A86301E

Q38062852-9F425C61-44E9-412D-A7C2-51C376FCCCEA

Q38062852-A75CF622-5B33-4362-90E4-E716FED77532

P2860

Q38062852-07622507-7E5A-4B0D-A4FD-3B219FDF2126

Q38062852-22FF38E5-C134-45C0-9E05-D7D0B86E4C6C

Q38062852-2F540599-7EFD-44A1-A68E-E2354A46D2A9

Q38062852-303B3FBF-C39D-4ECF-ADA9-A7019460B7F6

Q38062852-333C4D64-CFDD-4570-B096-C11FDB646229

Q38062852-3443824C-9CF1-4681-8F4F-E11E811FB193

Q38062852-50817AA1-99FC-4459-911B-9AFCB76CE15B

Q38062852-5149678C-6BDC-47F7-B493-EBC774C35C12

Q38062852-645CE33F-0D58-41A4-AC8A-ADE5C2D56449

Q38062852-7750A7CA-7791-4259-B28F-EB3B7F81C852

P2888

Q38062852-0DCBE69B-3C0B-443D-A9A8-C4B44101DBBD

P304

Q38062852-01F4DD3E-FC1A-4AF8-86CE-94218075D9A7

P31

Q38062852-FCA0D8E6-0DDC-418B-9116-DCC64421FFF3

P356

Q38062852-AA60D950-B44E-474C-AFFA-FD5460B8817E

P433

Q38062852-FF50B6A8-4732-47E1-93B2-73D2C3A57F93

P478

Q38062852-4A4E8E16-4A84-4515-9DD9-DA7379A23B7B

P577

Q38062852-D20BFCDA-F7B4-47B1-84FC-42C5D77F768D

P698

Q38062852-C4BA3BDA-B3F1-4103-962D-D482A4F1D52C

P356

S11102-012-0445-1

P1433

P1476

Growth hormone granulation pat ...... arge single center experience.

@en

P2093

Chris G Yedinak

http://www.w3.org/2001/XMLSchema#string

Jessica Brzana

http://www.w3.org/2001/XMLSchema#string

Johnny B Delashaw

http://www.w3.org/2001/XMLSchema#string

Maria Fleseriu

http://www.w3.org/2001/XMLSchema#string

Sakir H Gultekin

http://www.w3.org/2001/XMLSchema#string

P2860

Acromegaly pathogenesis and treatment

Growth hormone-secreting adenomas: pathology and cell biology.

Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form.

Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension

Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review.

Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients.

The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome.

The pathophysiological consequences of somatostatin receptor internalization and resistance.

Clinical, quality of life, and economic value of acromegaly disease control

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.

P2888

s11102-012-0445-1

P304

490-498

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11102-012-0445-1

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23184260

http://www.w3.org/2001/XMLSchema#string